Peptide Graded

Mecasermin

Is Mecasermin safe?

Hypoglycemia rates from label data

BSome human evidenceFDA approvedas of 2026-10-26

Hypoglycemia is the most common side effect. It was reported in about half of children in the registration studies, and a few had seizures. The label also lists enlarged tonsils and adenoids, which can cause snoring and sleep apnea. It lists intracranial hypertension, fat buildup at injection sites and worsening of scoliosis. It also lists slipped capital femoral epiphysis, a hip problem of fast-growing children. 12

IGF-1 drives cell growth. So the label bars its use in children with cancer or a history of cancer. It is unknown whether long-term IGF-1 exposure raises cancer risk later in life. The treated group is small and follow-up is limited. Adults using it off-label have no safety data to draw on. 2

Read the full Mecasermin page

More on Mecasermin

Citations

  1. Chernausek 2007, J Clin Endocrinol Metab: Long-term treatment with recombinant IGF-1 in children with severe IGF-1 deficiency doi.org
  2. FDA 2025: Increlex (mecasermin) prescribing information accessdata.fda.gov

Reference information only, not medical advice. Drawn from the Mecasermin article, fact-checked against the cited sources. No dosing anywhere on this site.